CN107519143A - A kind of antibacterial combination and preparation method thereof - Google Patents
A kind of antibacterial combination and preparation method thereof Download PDFInfo
- Publication number
- CN107519143A CN107519143A CN201710848646.9A CN201710848646A CN107519143A CN 107519143 A CN107519143 A CN 107519143A CN 201710848646 A CN201710848646 A CN 201710848646A CN 107519143 A CN107519143 A CN 107519143A
- Authority
- CN
- China
- Prior art keywords
- preparation
- tedizolid phosphate
- ato
- compritol
- toluene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to pharmaceutical technology field, and in particular to a kind of antibacterial combination and preparation method thereof.Said composition includes Tedizolid Phosphate, microcrystalline cellulose, starch, toluene di-tert-butyl phenol, polacrilin potassium, Compritol 888 ATO.Tedizolid Phosphate, microcrystalline cellulose, starch, toluene di-tert-butyl phenol, polacrilin potassium, Compritol 888 ATO are added 5% hydroxypropyl methylcellulose solution by the preparation method, and piece agent is prepared by tabletting after wet granulation.Preparation method of the present invention is simple, overcome the easy moisture absorption of Tedizolid Phosphate piece that prior art wet granulation obtains, the technical barrier such as dissolution rate is not high, stability is poor, obtained tablet is not easy moisture absorption caking and mobility, dissolution rate height are advantageous to the safe handling of clinical medicine and long-term storage.
Description
Technical field
The present invention relates to pharmaceutical technology field, more particularly to a kind of antibacterial combination and preparation method thereof, specifically relate to
A kind of and Tedizolid Phosphate composition tablet and preparation method thereof.
Background technology
Tedizolid Phosphate (tedizolid phosphate) is a kind of mouth oxazole of Cubist drugmakers of U.S. exploitation
Alkane ketone antibiotic, trade name Sivextro, for treating staphylococcus aureus (including methicillin resistant strains and methoxy
XiLin sensitive strain), adult acute's bacterial cutaneous and the skin caused by gram-positive bacteria such as various streptococcus and enterococcus
Tissue infection.Sivextro medicinal ingredient is the sodium salt of the safe ground azoles amine of phosphoric acid, existing two kinds of formulations of injection and tablet, in 2014
Obtain U.S. FDA approval listing on June 20, in.
CN106236718A discloses a kind of pharmaceutical composition of Tedizolid Phosphate and preparation method thereof, and it uses wet method
Tablet made from granulation has stabilization, safety, absorbs soon, dissolves the advantages that fast.Applicant have discovered that using wet granulation system
Tedizolid Phosphate tablet stability it is poor, dissolution rate is low, and hygroscopicity is obvious, has a strong impact on clinical application security and stably
Property.
Suitable preparation method and process conditions, the species of filler and disintegrant and dosage and filler and disintegrant
Appropriate combination it is most important to the result of extraction of capsule, mobility, content uniformity and stability.Conventional filler has shallow lake
Powder, lactose etc., conventional disintegrant have microcrystalline cellulose, sodium carboxymethyl starch etc., and conventional lubricant has talcum powder, stearic acid
Magnesium, silica, superfine silica gel powder, sodium stearyl fumarate, lauryl sodium sulfate etc..But how to pass through suitable prescription, work
Skill obtains more excellent dissolution rate, improves its mobility and content uniformity, further improves its stability, prior art is always
Do not broken through.And wet granulation preparation method is because of its unique advantage that (high income, low for equipment requirements, technique is simple, cost
It is low, it is more suitable for industrialized production), turn into the optimal selection of this area.And how to pass through the obtained dissolution of wet granulation preparation method
The Tedizolid Phosphate piece that degree is high, stability is good, hygroscopicity is low turns into the technical barrier and study hotspot of this area.
The present invention is controlled, gained Tedizolid Phosphate by substantial amounts of experimental study by the screening to auxiliary material and dosage
Composition tablet stability significantly improves, and successfully overcomes the Tedizolid Phosphate piece that existing wet granulation method obtains and easily inhales
The wet, technical barrier such as dissolution rate is not high, stability is poor, obtains that a kind of stability is high, good fluidity, and content uniformity is low, dissolution rate
Height, moisture absorption is not easy, greatly improves the security of medication and the Tedizolid Phosphate piece of validity.
The content of the invention
In view of this, the present invention provides a kind of more preferable Tedizolid Phosphate composition tablet of stability and its preparation side
Method；So that the Tedizolid Phosphate tablet stability is high, good fluidity, content uniformity is low, and dissolution rate is high, is not easy moisture absorption, significantly
Improve the security and validity of medication.
In order to realize foregoing invention purpose, the present invention provides following technical scheme：
An object of the present invention is to provide a kind of Tedizolid Phosphate composition tablet, and its described composition includes phosphorus
Acid specially azoles amine, microcrystalline cellulose, starch, toluene di-tert-butyl phenol, polacrilin potassium, Compritol 888 ATO.
Preferably, with weight, the composition includes：Tedizolid Phosphate 25%-30%, crystallite are fine
Tie up plain 30%-35%, starch 22%-26%, toluene di-tert-butyl phenol 0.1%-0.3%, polacrilin potassium 14%-18%,
Compritol 888 ATO 0.4%-0.6%.
Preferably, with weight, the composition includes：Tedizolid Phosphate 27%, microcrystalline cellulose
32.5%th, starch 24%, toluene di-tert-butyl phenol 0.2%, polacrilin potassium 15.8%, Compritol 888 ATO 0.5%.
It is easily tacky after Tedizolid Phosphate raw material moisture absorption, cause hardness to become big, cause disintegration difficult, dissolution rate is slack-off.
So if auxiliary material selects bad, easy moisture absorption, quality is unstable during causing finished product storage.Pharmaceutical composition is made
In, the generally auxiliary material of more likely few selection, and the stripping quantity of active component is bigger so can be with the reduction auxiliary material of maximum possible
Influence to active component, preparation technology is simplified, while reduce cost.Which but can specifically be reached from auxiliary material
Purpose is stated, it is necessary to which paying performing creative labour could realize, the present invention Tedizolid Phosphate composition prescription is carried out
Substantial amounts of screening, the composition of the Tedizolid Phosphate composition of the present invention is finally determined.
In view of the easy moisture absorption of Tedizolid Phosphate, to damp and hot unstable, inventor has found by analysis of experiments, phosphoric acid specially azoles
The mobility of amine and starch is poor, easily causes the bad control of loading amount, is made troubles to production.The present inventor is by substantial amounts of real
Screening is tested to find：Polacrilin potassium, Compritol 888 ATO synergy, significantly improve mobility, ensure that large-scale production process
Middle content uniformity is small, while is found by experiment, and it, which acts synergistically, significantly improves the dissolution rate of Tedizolid Phosphate；Shen simultaneously
Ask someone surprisingly to find that the addition of appropriate toluene di-tert-butyl phenol significantly reduces its hygroscopicity.
It is a further object of the present invention to provide a kind of preparation method of Tedizolid Phosphate composition tablet, methods described
Using wet granulation technology, it is concretely comprised the following steps：
(1) stock up：Tedizolid Phosphate, microcrystalline cellulose, starch, toluene di-tert-butyl phenol, polacrilin potassium are mixed
Crush, sieve after conjunction；Hypromellose is configured to 5% solution, it is standby as adhesive；
(2) pelletize：Material after pulverizing and sieving is added in wet granulator and is well mixed, adds 5% hydroxypropyl first
Cellulose solution softwood, pelletize, dry, whole grain；
(3) it is total mixed：Add Compritol 888 ATO to be placed in three-dimensional mixer particle after whole grain to be well mixed；
(4) tabletting.
The physicochemical property, stability feature and tablet dose formulation that present invention applicant furthers investigate Tedizolid Phosphate are special
Point, select suitable drug ingedient collaboration Tedizolid Phosphate that novel troche is made using wet granulation according to these features.
Preferably, step (1) sieving is first to cross 80 mesh sieves, after 100 mesh sieves.
Preferably, step (1) sieving is first to cross 80 mesh sieves, then repeatedly after 100 mesh sieve twice.
Preferably, step (2) the mixing rotating speed is 400-600 revs/min, incorporation time is 5-6 minutes.
Preferably, step (2) granulation is pelletized for 18 mesh sieves, the drying is 45 DEG C and dried 30 minutes, described whole
Grain is 20 mesh sieve whole grains.
Preferably, step (3) the mixing rotating speed is 10-15 revs/min, incorporation time is 8-10 minutes.
The invention has the advantages that：
(1) present composition synergy significantly improves mobility, the dissolution rate of said composition, and it is poor to reduce loading amount
It is different, it is more suitable for industrialized production.
(2) addition of toluene di-tert-butyl phenol significantly reduces its hygroscopicity.
(3) present invention is controlled by the screening to auxiliary material and dosage, gained Tedizolid Phosphate composition tablet stability
Significantly improve, it is not high, stably successfully to overcome the easy moisture absorption of Tedizolid Phosphate piece, dissolution rate that existing wet granulation method obtains
Property the technical barrier such as difference, obtain that a kind of stability is high, good fluidity, content uniformity is low, and dissolution rate is high, is not easy moisture absorption, carries significantly
The security of high medication and the Tedizolid Phosphate piece of validity.
Embodiment
The invention discloses a kind of Tedizolid Phosphate composition tablet, those skilled in the art can be used for reference in this paper
Hold, be suitably modified technological parameter realization.In particular, all similar replacements and change are to those skilled in the art
For be it will be apparent that they are considered as being included in the present invention.The method of the present invention and application are by preferably implementing
Example is described, related personnel substantially can not depart from present invention, in spirit and scope to method described herein and
Using being modified or suitably change with combining, to realize and using the technology of the present invention.
With reference to embodiment, the present invention is expanded on further：
The weight percentage (%) of embodiment 1-5 each components
| Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | |
| Tedizolid Phosphate | 25 | 27 | 30 | 27.5 | 25.4 |
| Microcrystalline cellulose | 35 | 32.5 | 31.3 | 30 | 33 |
| Starch | 25.4 | 24 | 22 | 26 | 23 |
| Toluene di-tert-butyl phenol | 0.1 | 0.2 | 0.3 | 0.1 | 0.2 |
| Polacrilin potassium | 14 | 15.8 | 16 | 15.8 | 18 |
| Compritol 888 ATO | 0.5 | 0.5 | 0.4 | 0.6 | 0.4 |
Preparation method：
(1) stock up：Tedizolid Phosphate, microcrystalline cellulose, starch, toluene di-tert-butyl phenol, polacrilin potassium are mixed
Crushed after conjunction, first cross 80 mesh sieves, then repeatedly after 100 mesh sieve twice；Hypromellose is configured to 5% solution, as bonding
Agent is standby；
(2) pelletize：Material after pulverizing and sieving is added in wet granulator and is well mixed, mixing rotating speed is 400-
600 revs/min, incorporation time is 5-6 minutes；5% hydroxypropyl methylcellulose solution softwood is added, the granulation of 18 mesh sieves, 45 DEG C dry
Dry 30 minutes, 20 mesh sieve whole grains；
(3) it is total mixed：Add Compritol 888 ATO to be placed in three-dimensional mixer particle after whole grain to be well mixed, mixing rotating speed is
10-15 revs/min, incorporation time is 8-10 minutes；
(4) tabletting.
Comparative example 1
The Tedizolid Phosphate piece being prepared with reference to the A embodiments 1 of patent CN 106236718.
Comparative example 2
CN is used using the B embodiment formulas of CN 101982468 (specification 0419-0421 sections tablet formulation)
Tedizolid Phosphate piece is made by adhesive of 60% ethanol in 106236718 A wet granulation methods.
Comparative example 3
The Tedizolid Phosphate piece being prepared with reference to the A embodiments 1 of patent CN 105496976.
Comparative example 4
Prescription：Tedizolid Phosphate 27%, microcrystalline cellulose 32.5%, starch 24%, polacrilin potassium 15.8%, behenyl
Acid glyceride 0.5%.(with weight).
Preparation method：
(1) stock up：Crushed after Tedizolid Phosphate, microcrystalline cellulose, starch, polacrilin potassium are mixed, first cross 80 mesh
Sieve, then repeatedly after 100 mesh sieve twice；Hypromellose is configured to 5% solution, it is standby as adhesive；
(2) pelletize：Material after pulverizing and sieving is added in wet granulator and is well mixed, mixing rotating speed is 400-
600 revs/min, incorporation time is 5-6 minutes；5% hydroxypropyl methylcellulose solution softwood is added, the granulation of 18 mesh sieves, 45 DEG C dry
Dry 30 minutes, 20 mesh sieve whole grains；
(3) it is total mixed：Add Compritol 888 ATO to be placed in three-dimensional mixer particle after whole grain to be well mixed, mixing rotating speed is
10-15 revs/min, incorporation time is 8-10 minutes；
(4) tabletting.
Comparative example 5
Prescription：Tedizolid Phosphate 27%, microcrystalline cellulose 32.5%, starch 24%, toluene di-tert-butyl phenol
0.2%th, polacrilin potassium 15.8%, Compritol 888 ATO 0.5%.(with weight).
Preparation method：
(1) stock up：Tedizolid Phosphate, microcrystalline cellulose, starch, toluene di-tert-butyl phenol, polacrilin potassium are mixed
Crushed after conjunction, first cross 80 mesh sieves, then repeatedly after 100 mesh sieve twice；Ethanol is configured to 60% solution, it is standby as adhesive
With；
(2) pelletize：Material after pulverizing and sieving is added in wet granulator and is well mixed, mixing rotating speed is 400-
600 revs/min, incorporation time is 5-6 minutes；Add 60% ethanol solution softwood, the granulation of 18 mesh sieves, 45 DEG C of 30 points of dryings
Clock, 20 mesh sieve whole grains；
(3) it is total mixed：Add Compritol 888 ATO to be placed in three-dimensional mixer particle after whole grain to be well mixed, mixing rotating speed is
10-15 revs/min, incorporation time is 8-10 minutes；
(4) tabletting.
Comparative example 6
Prescription：Tedizolid Phosphate 27%, microcrystalline cellulose 32.5%, starch 24%, toluene di-tert-butyl phenol
0.2%th, polacrilin potassium 15.8%, Compritol 888 ATO 0.5%.(with weight).
Preparation method：
(1) stock up：Tedizolid Phosphate, microcrystalline cellulose, starch, toluene di-tert-butyl phenol, polacrilin potassium are mixed
Crushed after conjunction, first cross 80 mesh sieves, then repeatedly after 100 mesh sieve twice；PVP K30 is configured to 5% solution, as adhesive
It is standby；
(2) pelletize：Material after pulverizing and sieving is added in wet granulator and is well mixed, mixing rotating speed is 400-
600 revs/min, incorporation time is 5-6 minutes；Add 5% PVP K30 solution softwood, the granulation of 18 mesh sieves, 45 DEG C of dryings 30
Minute, 20 mesh sieve whole grains；
(3) it is total mixed：Add Compritol 888 ATO to be placed in three-dimensional mixer particle after whole grain to be well mixed, mixing rotating speed is
10-15 revs/min, incorporation time is 8-10 minutes；
(4) tabletting.
Test method：
1st, mobility-detected is tested：
The mobility of solid can not be expressed with single characteristic value, commonly use angle of repose (angle of repose) and represent.
Typically refer to the maximum angular that the free inclined-plane of powder accumulation horizon and horizontal plane are formed.Angle of repose is smaller, and frictional force is smaller, flowing
Property is better, it is considered that good fluidity during θ≤30 degree, the need for liquidity in production process can be met during θ≤40 degree.Powder
Mobility the weight differential of the preparations such as granule, capsule, tablet and normal operating are had a great influence.
Inventor uses injection method：Powder is slowly added into above funnel, the material spilt from funnel bottom is in level
The inclination angle of coniform accumulation body is formed on face.Determine 3 times, average altogether.
2nd, dissolution rate detects
Dissolution method (two methods of annex XC second of Chinese Pharmacopoeia version in 2010) is shone using HPLC Examples 1-5,
Using water 900ml as solvent, rotating speed is 50 turns per minute, is taken a little at 30 minutes respectively, precision is measured in filtrate 5ml → 50ml measuring bottles
It is diluted with water to scale to shake up, mends dissolution fluid 5ml, according to AAS (A of annex IV), determines and absorb at 274nm wavelength
Degree.
3rd, draws moist test is according to the medicine draws moist test guideline of 2015 editions general rules of Chinese Pharmacopoeia 9103.
Specific test method is as follows：
Dry tool plug glass measuring cup (external diameter 50mm, a height of 15mm) is taken, suitable 25 are placed in experiment the previous day
(design temperature is 25 DEG C for DEG C of ± 1 DEG C thermostatic drier (placing ammonium chloride or ammonium sulfate saturated solution in bottom) or growth cabinet
± 1 DEG C, relative humidity is 80% ± 2%) in, accurately weighed weight (m1).
Take test sample appropriate, be laid in above-mentioned measuring cup, test sample thickness is about 1mm, accurately weighed weight (m2).
Measuring cup is open, and with bottle cap with being placed under the conditions of above-mentioned constant temperature and humidity 24 hours.
Cover measuring cup lid, accurately weighed weight (m3).
Percentage weight increase=(m3-m2)/(m2-m1) × 100%
Draw moist feature description with drawing defining for moist weightening
Deliquescence：Absorb enough moisture and form liquid.
It is great draw it is moist：Draw wet weightening and be not less than 15%.
Have draw it is moist：Draw wet weightening less than 15% but not less than 2%.
Slightly draw moist：Draw wet weightening less than 2% but not less than 0.2%.
Nothing is moist almost without drawing：Draw wet weightening and be less than 0.2%.
Experimental example 1：Performance detection
Comparison according to 1-5 of the embodiment of the present invention and comparative example 1-5 Tedizolid Phosphate piece performances prepared is shown in Table 1：
The performance test results of table 1
As can be seen from the above table, dissolution rate height, the good fluidity of Tedizolid Phosphate piece of the invention, content uniformity is low,
Hygroscopicity significantly reduces, and its performance is significantly better than existing preparation Tedizolid Phosphate piece.
Experimental example 2：Accelerated test
The sample of the embodiment of the present invention 2 is taken to place 6 under conditions of 40 DEG C ± 2 DEG C of temperature, relative humidity is 75% ± 5%
Month, respectively at the 1st, 2,3,6 the end of month sampling once, it is measured by stability high spot reviews project.Result of the test is shown in Table 2.
The accelerated test result of table 2
Identical experiment has been carried out to other embodiments of the invention, obtained and 1,2 similar result of the embodiment of the present invention；By
Experimental result can be seen that product of the embodiment of the present invention under conditions of 40 DEG C ± 2 DEG C of temperature, relative humidity are 75% ± 5%,
In character, dissolution rate, higher stability is respectively provided with about material, crystal formation etc..
Embodiment 3：Long term test
It is respectively 25 DEG C in temperature to take the embodiment of the present invention 1, the sample of embodiment 2, and relative humidity is 60% ± 10% bar
Place 24 months under part, respectively at the 3rd, 6,9,12,18,24 the end of month sampling once, carried out by stability high spot reviews project
Measure.Result of the test is shown in Table 3.
The long-term test results of table 3
Identical experiment has been carried out to other embodiments of the invention, obtained similar to the embodiment of the present invention 1, embodiment 2
As a result；Product of the present invention is in 40 DEG C ± 2 DEG C of temperature, the condition that relative humidity is 75% ± 5% it can be seen from experimental result
Under, in character, dissolution rate, higher stability is respectively provided with about material, crystal formation etc..
Described above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (9)
1. a kind of antibacterial combination, it is characterised in that the composition includes Tedizolid Phosphate, microcrystalline cellulose, shallow lake
Powder, toluene di-tert-butyl phenol, polacrilin potassium, Compritol 888 ATO.
2. antibacterial combination according to claim 1, it is characterised in that with weight, the combination
Thing includes：Tedizolid Phosphate 25%-30%, microcrystalline cellulose 30%-35%, starch 22%-26%, di-t-butyl are to toluene
Phenol 0.1%-0.3%, polacrilin potassium 14%-18%, Compritol 888 ATO 0.4%-0.6%.
3. antibacterial combination according to claim 2, it is characterised in that with weight, the composition
Including：Tedizolid Phosphate 27%, microcrystalline cellulose 32.5%, starch 24%, toluene di-tert-butyl phenol 0.2%, Andrea Pollack
Woods potassium 15.8%, Compritol 888 ATO 0.5%.
4. a kind of preparation method of antibacterial combination, it is characterised in that comprise the following steps：
(1) stock up：After Tedizolid Phosphate, microcrystalline cellulose, starch, toluene di-tert-butyl phenol, polacrilin potassium are mixed
Crush, sieving；Hypromellose is configured to 5% solution, it is standby as adhesive；
(2) pelletize：Material after pulverizing and sieving is added in wet granulator and is well mixed, adds 5% hypromellose
Plain solution softwood, pelletize, dry, whole grain；
(3) it is total mixed：Add Compritol 888 ATO to be placed in three-dimensional mixer particle after whole grain to be well mixed；
(4) tabletting.
5. preparation method according to claim 4, it is characterised in that step (1) sieving is first to cross 80 mesh sieves, after
100 mesh sieves.
6. preparation method according to claim 5, it is characterised in that step (1) sieving is first to cross 80 mesh sieves, then instead
Answered 100 mesh sieve twice.
7. preparation method according to claim 4, it is characterised in that step (2) it is described mixing rotating speed be 400-600 turn/
Point, incorporation time is 5-6 minutes.
8. preparation method according to claim 4, it is characterised in that step (2) granulation is pelletized for 18 mesh sieves, described
Dry and dried 30 minutes for 45 DEG C, the whole grain is 20 mesh sieve whole grains.
9. preparation method according to claim 4, it is characterised in that step (3) the mixing rotating speed is 10-15 revs/min
Clock, incorporation time are 8-10 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710848646.9A CN107519143A (en) | 2017-09-20 | 2017-09-20 | A kind of antibacterial combination and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710848646.9A CN107519143A (en) | 2017-09-20 | 2017-09-20 | A kind of antibacterial combination and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107519143A true CN107519143A (en) | 2017-12-29 |
Family
ID=60736961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710848646.9A Pending CN107519143A (en) | 2017-09-20 | 2017-09-20 | A kind of antibacterial combination and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107519143A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105496976A (en) * | 2015-12-18 | 2016-04-20 | 北京万全德众医药生物技术有限公司 | Eltrombopag tablet and preparation method thereof |
| CN105640903A (en) * | 2014-11-11 | 2016-06-08 | 天津市汉康医药生物技术有限公司 | Stable tedizolid phosphate medicine composition |
| CN106236718A (en) * | 2016-08-29 | 2016-12-21 | 海南通用康力制药有限公司 | A kind of pharmaceutical composition of Tedizolid Phosphate and preparation method thereof |
| CN107536824A (en) * | 2017-09-12 | 2018-01-05 | 甘宜玲 | A kind of preparation method of acotiamide hydrochloride hydrate composition capsule |
-
2017
- 2017-09-20 CN CN201710848646.9A patent/CN107519143A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105640903A (en) * | 2014-11-11 | 2016-06-08 | 天津市汉康医药生物技术有限公司 | Stable tedizolid phosphate medicine composition |
| CN105496976A (en) * | 2015-12-18 | 2016-04-20 | 北京万全德众医药生物技术有限公司 | Eltrombopag tablet and preparation method thereof |
| CN106236718A (en) * | 2016-08-29 | 2016-12-21 | 海南通用康力制药有限公司 | A kind of pharmaceutical composition of Tedizolid Phosphate and preparation method thereof |
| CN107536824A (en) * | 2017-09-12 | 2018-01-05 | 甘宜玲 | A kind of preparation method of acotiamide hydrochloride hydrate composition capsule |
Non-Patent Citations (2)
| Title |
|---|
| 张驰等: "磷酸特地唑胺片的处方工艺及体外溶出行为的研究", 《中国抗生素杂志》 * |
| 高峰主编: "《药用高分子材料学》", 31 October 2014, 华东理工大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107875136B (en) | Amoxicillin medicinal preparation and preparation method thereof | |
| KR100981905B1 (en) | Solid preparation containing single crystal form | |
| EP1884242A1 (en) | Pharmaceutical composition | |
| CN101141961A (en) | Stable particular pharmaceutical composition of solifenacin or salt thereof | |
| CN103083278A (en) | Roxithromycin capsule and preparation method thereof | |
| CN105030705B (en) | A kind of cancer therapy drug erlotinib Hydrochloride tablet and preparation method thereof | |
| JP2016044170A (en) | Olmesartan prodrug formulation | |
| CN106999483A (en) | A kind of pharmaceutical composition containing quinoline or its salt | |
| CN102600132A (en) | Oral preparation containing amisulpride | |
| CN107595782A (en) | A kind of Linezolid dry suspensoid agent and preparation method thereof | |
| CN112603900A (en) | Solid preparation containing [ (4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl) -amino ] -acetic acid | |
| CN105358137A (en) | Sovaprevir tablets | |
| GB2595140A (en) | Flupentixol/melitracen pharmaceutical composition and preparation thereof | |
| CN106139156B (en) | A kind of pharmaceutical composition containing quinoline or its salt | |
| CN103372014A (en) | Quickly dissolved-out stable vardenafil hydrochloride oral solid preparation and preparation method thereof | |
| EP2692340B1 (en) | Stable pharmaceutical system (kit) for the preparation of oral solution of levothyroxine or pharmaceutically acceptable salt thereof | |
| CN101568329A (en) | Dry granulated pharmaceutical compositions and methods for producing same | |
| CN108553433A (en) | A kind of Azilsartan piece and preparation method thereof | |
| CN104940152A (en) | Pharmaceutical composition containing solifenacin succinate | |
| KR20160002177A (en) | Pharmaceutical composition comprising oseltamivir free base | |
| EP3148513B1 (en) | Ceritinib formulation | |
| CN107519143A (en) | A kind of antibacterial combination and preparation method thereof | |
| CN107375231A (en) | A kind of preparation method of olaparib composition capsule | |
| CN104473901B (en) | Cefdinir capsule and preparation method thereof | |
| CN111214456A (en) | Voriconazole dry suspension and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171229 |
|
| WD01 | Invention patent application deemed withdrawn after publication |